As investors were picking up the pieces after the dot-com implosion, they came across another troubled sector. A series of looming patent expirations on key drugs meant that major pharmaceutical companies were on the cusp of a decade-long sales drought. Investors responded by dumping shares, as the AMEX Pharmaceutical Index plunged from 400 in late 2001 to just 250 a… Read More
As investors were picking up the pieces after the dot-com implosion, they came across another troubled sector. A series of looming patent expirations on key drugs meant that major pharmaceutical companies were on the cusp of a decade-long sales drought. Investors responded by dumping shares, as the AMEX Pharmaceutical Index plunged from 400 in late 2001 to just 250 a year later. A decade later, Big Pharma’s “patent cliff” was still a key concern, and this index remained far from its previous highs. Yet in recent quarters, Big Pharma has come back with a vengeance, as shares have moved back to the levels seen all those years ago. Credit goes to several factors, most notably the absence of any new imminent blockbuster-drug patent expirations, and an industrywide focus on shareholder-friendly moves such as share… Read More